Evidence map›Paper›PMID 29486622›Full record

ReviewCell adhesion & migration2018

A novel functional crosstalk between DDR1 and the IGF axis and its relevance for breast cancer.

Antonino Belfiore, Roberta Malaguarnera, Maria Luisa Nicolosi, Rosamaria Lappano, Marco Ragusa, Andrea Morrione, Veronica Vella

Open access · goldAbstract readReview
In one paragraph

Review in Cell adhesion & migration, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 42 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. [MiR-6838-5p overexpression inhibits proliferation of breast cancer MCF-7 cells by downregulating DDR1 expression].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2024
    Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Complex roles of discoidin domain receptor tyrosine kinases in cancer.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

Antonino Belfiorea Endocrinology, Department of Clinical and Experimental Medicine , University of Catania, Garibaldi-Nesima Hospital , Catania , Italy.ORCID 0000-0002-6181-4193
Roberta Malaguarnerab Endocrinology, Department of Health Sciences , University Magna Graecia of Catanzaro , Catanzaro , Italy.
Maria Luisa Nicolosib Endocrinology, Department of Health Sciences , University Magna Graecia of Catanzaro , Catanzaro , Italy.
Rosamaria Lappanoc Department of Pharmacy , Health and Nutritional Sciences, University of Calabria , Rende , Italy.
Marco Ragusad Department of Biomedical and Biotechnological Sciences , Unit of BioMolecular, Genome, and Complex System BioMedicine, University of Catania , Catania , Italy.ORCID 0000-0002-4282-920X
Andrea Morrionee Department of Urology and Biology of Prostate Cancer Program , Sidney Kimmel Cancer Center, Thomas Jefferson University , Philadelphia , Pennsylvania.
Veronica Vellaa Endocrinology, Department of Clinical and Experimental Medicine , University of Catania, Garibaldi-Nesima Hospital , Catania , Italy.ORCID 0000-0002-4968-8550
Magna Graecia University · ITUniversity of Catania · ITThomas Jefferson University · USUniversità degli Studi di Enna Kore · ITUniversity of Calabria · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last decades increasing importance has been attributed to the Insulin/Insulin-like Growth Factor signaling (IIGFs) in cancer development, progression and resistance to therapy. In fact, IIGFs is often deregulated in cancer. In particular, the mitogenic insulin receptor isoform A (IR-A) and the insulin-like growth factor receptor (IGF-1R) are frequently overexpressed in cancer together with their cognate ligands IGF-1 and IGF-2. Recently, we identified discoidin domain receptor 1 (DDR1) as a new IR-A interacting protein. DDR1, a non-integrin collagen tyrosine kinase receptor, is overexpressed in several malignancies and plays a role in cancer progression and metastasis. Herein, we review recent findings indicating that DDR1 is as a novel modulator of IR and IGF-1R expression and function. DDR1 functionally interacts with IR and IGF-1R and enhances the biological actions of insulin, IGF-1 and IGF-2. Conversely, DDR1 is upregulated by IGF-1, IGF-2 and insulin through the PI3K/AKT/miR-199a-5p circuit. Furthermore, we discuss the role of the non-canonical estrogen receptor GPER1 in the DDR1-IIGFs crosstalk. These data suggest a wider role of DDR1 as a regulator of cell response to hormones, growth factors, and signals coming from the extracellular matrix.

Indexed as

Signal TransductionBreast NeoplasmsDiscoidin Domain Receptor 1FemaleHumansInsulin-Like Growth Factor IInsulin-Like Growth Factor IIModels, BiologicalDiscoidin Domain Receptor 1Insulin-Like Growth Factor IInsulin-Like Growth Factor IIbreast cancerdiscoidin domain receptor 1insulin-like growth factor-2insulin-like growth factor axisinsulin receptor isoform A

Identifiers

PMID29486622
PMCPMC6363032
OpenAlexW2789495192

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.